Public Investments in TB Medicine Bedaquiline Far Exceed Those of Developer Johnson & Johnson
A Lower Price for Rifapentine Is Just a Start – Communities Need More Than Discounts to Access TB Preventive Therapy
Open Letter to Cepheid: Time to Lower the Price of Xpert Cartridges to US $5
Statement: Truly Corrective Actions on Drug Pricing Will Bring Life-Saving Benefit to Consumers in the U.S. and Globally
This is a joint statement from TAG and Health GAP October 16, 2019 – Although Speaker Nancy Pelosi’s bill to increase affordable access to medicines in the U.S., H.R. 3, offers halting, partial steps to reduce drug prices for some…
The Tuberculosis Diagnostics Pipeline
July 2012 By Colleen Daniels and Coco Jervis Introduction Accurate tuberculosis (TB) diagnosis has the potential to be the cornerstone of all global TB control efforts. However, the poor accuracy of the most commonly used test, sputum smear microscopy, and…
National TB Checklist
Access to quality diagnosis, treatment, and prevention for tuberculosis (TB) is a human right. Are the necessary tests, treatments, vaccines, services and policies available where you live or work? This new checklist from Treatment Action Group (TAG) lays out simply…
TB Research Funding Trends
TAG's annual Report on Tuberculosis Research Funding Trends tracks how much public, private, philanthropic, and multilateral institutions spend on TB research and development (R&D) across six areas of research: basic science, diagnostics, drugs vaccines, operational research, and infrastructure/unspecified projects. The…
2019 Pipeline Report
Ensuring Treatment for Children with Orphan Diseases: Ending Exemptions from the Pediatric Research Equity Act (PREA)
August 27, 2019 – This policy brief was developed by TAG and the Elizabeth Glaser Pediatric AIDS Foundation (EGPAF), and it details how children with TB are affected by the pediatric research exemption for orphan drugs. The brief also proposes…